Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Table 1

In vitro antiproliferative activity of lenvatinib against human thyroid cancer cells.

Tissue type	Cell line	Lenvatinib
		(μM)	T/N^2
Normal	Nthy-ori 3-1	15	—
DTC^3	K1	22	1.47
	RO82-W-1	3.8	0.25
	FTC-133	24	1.6
	FTC-236	17	1.13
	FTC-238	18	1.2
MTC^4	TT	0.078	0.01
ATC^5	8305C	26	1.73
	8505C	26	1.73
	TCO-1	28	1.87
	KHM-5M	28	1.87
	HTC/C3	28	2.53

The half maximal inhibitory concentration.
²T/N: ratio of IC₅₀ values of thyroid cancer cell lines to that of Nthy-ori 3-1 cells.
³DTC: differentiated thyroid cancer.
⁴MTC: medullary thyroid cancer.
⁵ATC: anaplastic thyroid cancer.